John Cunningham Virus seroconversion during natalizumab treatment
Main Article Content
Abstract
Introduction: Multiple sclerosis is a progressive disease that is difficult to predict, originating in cases of disability. Natalizumab is a highly effective disease-modifying therapy but is associated with greater John Cunningham virus (JCV) reactivation and consequent increased risk of developing Progressive Multifocal Leukoencephalopathy (PML). Objective: To analyze JCV seroconversion in patients treated with natalizumab. Methods: A retrospective study was conducted involving patients diagnosed with multiple sclerosis, between January 2012 and December 2021. To assess seroconversion during treatment with natalizumab, patients were considered seronegative at the beginning of treatment and who had at least one result in the period of medication use. The study was approved by the Human Research Ethics Committee under protocol 3,177,442. Results: Sixty-two patients treated with Natalizumab were included, with a seroprevalence of 67.7%. At the start of treatment, 41.9% (26/62) of the patients were negative for anti-JCV, of which 23.1% (6/26) were seroconverted. The mean time to seroconversion was 2.5 years. The baseline index of anti-JCV antibodies was statistically significant with the age of the patients. Among patients with a negative anti-JCV antibody result at baseline, 82.6% (19/23) remained negative throughout monitoring. Treatment was discontinued in 53.2% (33/62) of patients, and 72.7% (24/33) due to anti-JCV positivity with a consumption index >1.5 in 41.9% of cases. Conclusion: Knowing how to monitor the anti-JCV antibody index and treatment approaches in our patient cohort may be useful in future clinical decisions in treating MS.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.References
Sá J. A propósito do artigo: o tratamento da esclerose múltipla com natalizumab: análise de uma coorte hospitalar. Acta Med Port. 2014;27(4):409-10.
Kolcava J, Hulova M, Benesova Y, Bednarik J, Stourac P. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab concerning demographic, clinical, and radiological findings. Mult Scler Relat Disord. 2019;30:187-91. https://doi.org/10.1016/j.msard.2019.02.019
Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143-52. https://doi.org/10.1177/1352458511435105
Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating human brain disease. Clin Microbiol. 2012;25(3):471-506. https://doi.org/10.1128/CMR.05031-11
Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021;360:577721. https://doi.org/10.1016/j.jneuroim.2021.577721
Snopková S, Štourač P, Fašaneková L, Mihalčin M, Havlíčková K, Svačinka R, et al. Progressive multifocal leukoencephalopathy - epidemiology, immune response, clinical differences, treatment. Epidemiol Mikrobiol Imunol. 2019;68(1):24-31.
Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925-33. https://doi.org/10.1016/S1474-4422(17)30282-X
Hegen H, Auer M, Bsteh G, Di Pauli F, Plavina T, Walde J, et al. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. PLoS One. 2017;12(3):e0174005. https://doi.org/10.1371/journal.pone.0174005
Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, et al. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57(2):141-6. https://doi.org/10.1016/j.jcv.2013.02.002
Branco LP, Adoni T, Apostolos-Pereira SL, Brooks JBB, Correa EC, Damasceno CA, et al. Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis. Arq Neuropsiquiatr. 2018;76(9):588-91. https://doi.org/10.1590/0004-282X20180083
Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho Mde J, et al. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive. Arq Neuropsiquiatr. 2013;71(10):780-2. https://doi.org/10.1590/0004-282X20130121
Dwyer CM, Jokubaitis VG, Stankovich J, Baker J, Haartsen J, Butzkueven H, et al. High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. Ther Adv Neurol Disord. 2021;14:1756286421998915. https://doi.org/10.1177/1756286421998915
Paz SPC, Branco L, Pereira MAC, Spessotto C, Fragoso YD. A systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitisoptica. Epidemiol Health. 2018;40:e2018001. https://doi.org/10.4178/epih.e2018001
Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B. Anti-JC virus (JCV) prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol. 2014;21(2):299-304. https://doi.org/10.1111/ene.12304
Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, et al. Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler. 2012;18(7):1054-5. https://doi.org/10.1177/1352458511429955
Bhan V, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, et al. Anti-JC Virus Antibody Prevalence in Canadian MS Patients. Can J Neurol Sci. 2014;41(6):748-52. https://doi.org/10.1017/cjn.2014.32
Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define the risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802-12. https://doi.org/10.1002/ana.24286
Alroughani R, Akhtar S, Ahmed SF, Khoury SJ, Al-Hashel JY, Sahraian MA, et al. JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle Eastern study. J Neurol Sci. 2016;360:61-5. https://doi.org/10.1016/j.jns.2015.11.044
Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, et al. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016;23(6):1079-85. https://doi.org/10.1111/ene.12988
Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, et al. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyomavirus seroconversion rates under natalizumab treatment and differences between technical and biological seroconverters. Mult Scler. 2018;24(5):563-73. https://doi.org/10.1177/1352458517728814
Gaughan M, Gilligan M, Patterson I, McGurgan I, Yap SM, Tubridy N, et al. Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis. Mult Scler Relat Disord. 2022;68:104251. https://doi.org/10.1016/j.msard.2022.104251
Bonek R, Guenter W, Jałowiński R, Karbicka A, Litwin A, Maciejowski M, et al. JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies. J Clin Med. 2021;10(9):1998. https://doi.org/10.3390/jcm10091998
Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, et al. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Invest. 2017;47(2):158-66. https://doi.org/10.1111/eci.12721
Sá MJ, Nunes CC, Silva AM, Mota P, Pinto-Marques J; Justify Investigators. JC virus antibodies in Portuguese multiple sclerosis patients: Justify study results. J Neurol Sci. 2019;406:116426. https://doi.org/10.1016/j.jns.2019.116426
Cambron M, Hadhoum N, Duhin E, Lacour A, Chouraki A, Vermersch P. JCV serology in time: 3 years of follow-up. Acta Neurol Scand. 2017;136(1):54-8. https://doi.org/10.1111/ane.12699
Raffel J, Gafson AR, Malik O, Nicholas R. Anti-JC virus antibody titers increase over time with natalizumab treatment. Mult Scler. 2015;21(14):1833-8. https://doi.org/10.1177/1352458515599681
Kim SH, Kim Y, Jung JY, Park NY, Jang H, Hyun JW, et al. High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis. J Clin Neurol. 2019;15(4):454-60. https://doi.org/10.3988/jcn.2019.15.4.454
Lau A, Qiu W, Kermode A, Au C, Ng A, Wong A, et al. High prevalence, and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis. Mult Scler J ExpTransl Clin. 2018;4(3):2055217318788699. https://doi.org/10.1177/2055217318788699
Grebenciucova E, Berger JR. Progressive Multifocal Leukoencephalopathy. Neurol Clin. 2018;36(4):739-50. https://doi.org/10.1016/j.ncl.2018.06.002
Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy. Acta Neurol Scand. 2017;136(Suppl 201):37-44. https://doi.org/10.1111/ane.12840
Outteryck O, Zéphir H, Salleron J, Ongagna JC, Etxeberria A, Collongues N, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. 2014;20(7):822-9. https://doi.org/10.1177/1352458513505353
Bigaut K, Fabacher T, Kremer L, Ongagna JC, Kwiatkowski A, Sellal F, et al. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. Mult Scler. 2021;27(5):729-41. https://doi.org/10.1177/1352458520936239
Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Natalizumab discontinuation in a Dutch real-world cohort. Mult Scler Relat Disord. 2021;52:102974. https://doi.org/10.1016/j.msard.2021.102974
Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord. 2022;65:103995. https://doi.org/10.1016/j.msard.2022.103995
Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S, et al. Italian MS Register Study Group. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(12):1297-303. https://doi.org/10.1136/jnnp-2020-323472
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. The risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452-62. https://doi.org/10.1212/WNL.0000000000008243
van Lierop Z, Toorop AA, Coerver E, Willemse E, Strijbis E, Kalkers NF, et al. Ocrelizumab after natalizumab in JC-virus positive relapsing-remitting multiple sclerosis patients. Mult Scler J Exp Transl Clin. 2021;7(2):20552173211013831. https://doi.org/10.1177/20552173211013831
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, et al. PANGAEA Study Group. Long-term real-world evidence for sustained clinical benefits of fingolimod the following switch from natalizumab. Mult Scler Relat Disord. 2019;39:101893. https://doi.org/10.1016/j.msard.2019.101893
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, et al. Austrian MS Treatment Registry (AMSTR). Switching from natalizumab to fingolimod treatment in multiple sclerosis: real-life data from the Austrian MS Treatment Registry. J Neurol. 2021;266(11):2672-7. https://doi.org/10.1007/s00415-019-09464-0
Zanghì A, Gallo A, Avolio C, Capuano R, Lucchini M, Petracca M, et al. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics. 2021;18(2):1166-74. https://doi.org/10.1007/s13311-021-01037-2